Building A Better Biomarker: PD-L1 Expression Under Spotlight At ASCO
With new data showing correlation to response, use of PD-L1 expression as a biomarker for PD-1/L1 inhibitors was a frequent topic at ASCO. Its limitations point to need for better markers to guide immunotherapy use.
You may also be interested in...
Survey of recent literature shows breadth and quality of early research activity aimed at developing biomarkers to predict response to PD-1 and CTLA-4 checkpoint inhibitors.
Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.
From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research.